This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jarvinen, T. A. Articles by Isola, J. Search for Related Content PubMed PubMed Citation Articles by Jarvinen, T. A. Articles by Isola, J.

American Journal of Pathology, Vol 148, 2073-2082, Copyright © 1996 by American Society for Investigative Pathology

REGULAR ARTICLES

Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer

TA Jarvinen, J Kononen, M Pelto-Huikko and J Isola
Laboratory of Cancer Genetics, University of Tampere, Tampere, Finland.

The role of molecular markers predicting the response to cytotoxic chemotherapy is not established. A potential predictive factor, topoisomerase IIalpha, is a target for certain cytotoxic drugs, and its concentration has been shown to correlate with chemosensitivity in vitro. We evaluated expression of topo IIalpha immunohistochemically in 230 breast cancer samples and studied its association with known clinicopathological factors and factors previously shown to predict response to cytotoxic drugs. Topo IIalpha protein expression was found in 0.6 to 39.4% (10.6 +/- 7.9%, mean +/- SD) of breast carcinoma cells, whereas expression was undetectable in nonmalignant breast epithelium. Topo IIalpha protein expression correlated well with semi-quantitative mRNA in situ hybridization (P = 0.007). A significant association was found between the proportion of topo-IIalpha-positive cells and low estrogen and progesterone receptor content (P<0.0001), high grade (P<0.0001), DNA aneuploidy (P=0.003), and c-erbB-2 oncoprotein overexpression (P<0.0001). Topo IIalpha expression was not associated with clinical variables, such as age of the patient, primary tumor size, or axillary nodal status. A highly significant linear correlation was found between topo IIalpha and tumor proliferation rate (S-phase fraction, r=0.46; P<0.0001). Because hormone receptors, grade, and ploidy are associated with tumor proliferation rate, topo IIalpha expression was adjusted for S-phase fraction to reveal the proliferation-independent clinopathological associations. According to the analysis of co-variance, only aneuploidy (P=0.0003) and c-erb-2 overexpression (P=0.01) were associated with proliferation-adjusted expression of topo IIalpha. In conclusion, the close association of Topo IIalpha with other potential predictive factors (tumor proliferation rate, c-erbB-2 oncoprotein) suggests that topo IIalpha, having a defined role as a target for cytotoxic drugs, may be a valuable predictor of response to chemotherapy.

This article has been cited by other articles:

				A. Gennari, M. P. Sormani, P. Pronzato, M. Puntoni, M. Colozza, U. Pfeffer, and P. Bruzzi HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials J Natl Cancer Inst, January 2, 2008; 100(1): 14 - 20. [Abstract] [Full Text] [PDF]

				A. Di Leo, S. Licitra, W. Claudino, and L. Biganzoli Molecular Predictors of Response to Anthracyclines ASCO Educational Book, January 1, 2008; 2008(1): 3 - 7. [Abstract] [Full Text] [PDF]

				L. Nakopoulou, E. G Panayotopoulou, I. Giannopoulou, I. Tsirmpa, S. Katsarou, E. Mylona, P. Alexandrou, and A. Keramopoulos Extra copies of chromosomes 16 and X in invasive breast carcinomas are related to aggressive phenotype and poor prognosis J. Clin. Pathol., July 1, 2007; 60(7): 808 - 815. [Abstract] [Full Text] [PDF]

				M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Onc., November 1, 2005; 16(11): 1723 - 1739. [Abstract] [Full Text] [PDF]

				A. S. Knoop, H. Knudsen, E. Balslev, B. B. Rasmussen, J. Overgaard, K. V. Nielsen, A. Schonau, K. Gunnarsdottir, K. E. Olsen, H. Mouridsen, et al. Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group J. Clin. Oncol., October 20, 2005; 23(30): 7483 - 7490. [Abstract] [Full Text] [PDF]

				J. P. Braybrooke, N. C. Levitt, S. Joel, T. Davis, S. Madhusudan, H. Turley, S. Wilner, A. L. Harris, and D. C. Talbot Pharmacokinetic Study of Cisplatin and Infusional Etoposide Phosphate in Advanced Breast Cancer with Correlation of Response to Topoisomerase II{alpha} Expression Clin. Cancer Res., October 15, 2003; 9(13): 4682 - 4688. [Abstract] [Full Text] [PDF]

				T. A. H. Jarvinen, L. Jozsa, P. Kannus, T. L. N. Jarvinen, T. Hurme, M. Kvist, M. Pelto-Huikko, H. Kalimo, and M. Jarvinen Mechanical loading regulates the expression of tenascin-C in the myotendinous junction and tendon but does not induce de novo synthesis in the skeletal muscle J. Cell Sci., March 1, 2003; 116(5): 857 - 866. [Abstract] [Full Text] [PDF]

				A. Varis, M. Wolf, O. Monni, M.-L. Vakkari, A. Kokkola, C. Moskaluk, H. Frierson Jr., S. M. Powell, S. Knuutila, A. Kallioniemi, et al. Targets of Gene Amplification and Overexpression at 17q in Gastric Cancer Cancer Res., May 1, 2002; 62(9): 2625 - 2629. [Abstract] [Full Text] [PDF]

				N. Germann, M. Gross-Goupil, E. Wasserman, J.-F. Emile, J.-L. Misset, M. Reynes, and F. Goldwasser The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of {alpha}-fetoprotein or {beta}-human chorionic gonadotrophin: report of two cases Ann. Onc., April 1, 2002; 13(4): 632 - 636. [Abstract] [Full Text] [PDF]

				L. N. Harris, L. Yang, V. Liotcheva, S. Pauli, J. D. Iglehart, O. M. Colvin, and T. S. Hsieh Induction of Topoisomerase II Activity after ErbB2 Activation Is Associated with a Differential Response to Breast Cancer Chemotherapy Clin. Cancer Res., June 1, 2001; 7(6): 1497 - 1504. [Abstract] [Full Text] [PDF]

				T. Petit, C. Borel, J.-P. Ghnassia, J.-F. Rodier, A. Escande, R. Mors, and P. Haegele Chemotherapy Response of Breast Cancer Depends on HER-2 Status and Anthracycline Dose Intensity in the Neoadjuvant Setting Clin. Cancer Res., June 1, 2001; 7(6): 1577 - 1581. [Abstract] [Full Text] [PDF]

				A J Lodge, A G Hall, M M Reid, G G McIntosh, M Steward, J J Anderson, C H W Horne, and B Angus Topoisomerase II{{alpha}} and II{beta} expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome J. Clin. Pathol., January 1, 2001; 54(1): 31 - 36. [Abstract] [Full Text] [PDF]

				T. A. H. Jarvinen, M. Tanner, V. Rantanen, M. Barlund, A. Borg, S. Grenman, and J. Isola Amplification and Deletion of Topoisomerase II{alpha} Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer Am. J. Pathol., March 1, 2000; 156(3): 839 - 847. [Abstract] [Full Text] [PDF]

				T. A. H. Jarvinen, M. Pelto-Huikko, K. Holli, and J. Isola Estrogen Receptor {beta} Is Coexpressed with ER{alpha} and PR and Associated with Nodal Status, Grade, and Proliferation Rate in Breast Cancer Am. J. Pathol., January 1, 2000; 156(1): 29 - 35. [Abstract] [Full Text] [PDF]

				P. C. Goswami, J. Sheren, L. D. Albee, A. Parsian, J. E. Sim, L. A. Ridnour, R. Higashikubo, D. Gius, C. R. Hunt, and D. R. Spitz Cell Cycle-coupled Variation in Topoisomerase IIalpha mRNA Is Regulated by the 3'-Untranslated Region. POSSIBLE ROLE OF REDOX-SENSITIVE PROTEIN BINDING IN mRNA ACCUMULATION J. Biol. Chem., December 1, 2000; 275(49): 38384 - 38392. [Abstract] [Full Text] [PDF]